Uri Tabori
A5010939758- Glioma Diagnosis and Treatment
- Neuroblastoma Research and Treatments
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Genetic factors in colorectal cancer
- Chromatin Remodeling and Cancer
- Epigenetics and DNA Methylation
- Neurofibromatosis and Schwannoma Cases
- Meningioma and schwannoma management
- Ocular Oncology and Treatments
- Sarcoma Diagnosis and Treatment
- Childhood Cancer Survivors' Quality of Life
- Cancer, Hypoxia, and Metabolism
- Brain Metastases and Treatment
- Cancer-related Molecular Pathways
- Hedgehog Signaling Pathway Studies
- DNA Repair Mechanisms
- Telomeres, Telomerase, and Senescence
- RNA modifications and cancer
- Radiomics and Machine Learning in Medical Imaging
- Pancreatic and Hepatic Oncology Research
- Medical Imaging and Pathology Studies
- Protein Degradation and Inhibitors
- Histone Deacetylase Inhibitors Research
- Lung Cancer Treatments and Mutations
University of Toronto
2016-2025
Hospital for Sick Children
2016-2025
SickKids Foundation
2015-2024
Johns Hopkins University
2013-2024
Occupational Cancer Research Centre
2014-2024
California University of Pennsylvania
2024
Rush University Medical Center
2024
Washington University in St. Louis
2024
Cleveland Clinic
2024
Brigham and Women's Hospital
2024
High tumor mutational burden (TMB) is an emerging biomarker of sensitivity to immune checkpoint inhibitors and has been shown be more significantly associated with response PD-1 PD-L1 blockade immunotherapy than or expression, as measured by immunohistochemistry (IHC). The distribution TMB the subset patients high not well characterized in majority cancer types. In this study, we compare a targeted comprehensive genomic profiling (CGP) assay exome sequencing simulate expected variance when...
Recurrent glioblastoma multiforme (GBM) is incurable with current therapies. Biallelic mismatch repair deficiency (bMMRD) a highly penetrant childhood cancer syndrome often resulting in GBM characterized by high mutational burden. Evidence suggests that mutation and neoantigen loads are associated response to immune checkpoint inhibition.We performed exome sequencing prediction on 37 bMMRD cancers compared them adult brain neoplasms. Neoantigen was responsive from multiple tissues. Two...
cIMPACT-NOW (the Consortium to Inform Molecular and Practical Approaches CNS Tumor Taxonomy) was established evaluate make practical recommendations on recent advances in the field of tumor classification, particularly light rapid progress molecular insights into these neoplasms. For Round 2 its deliberations, Working Committee 3 reconstituted convened Utrecht, The Netherlands, for a meeting designed review putative new types advance any future World Health Organization classification. In...
Reports detailing the prognostic impact of TP53 mutations in medulloblastoma offer conflicting conclusions. We resolve this issue through inclusion molecular subgroup profiles.We determined affiliation, mutation status, and clinical outcome a discovery cohort 397 medulloblastomas. subsequently validated our results on an independent 156 medulloblastomas.TP53 are enriched wingless (WNT; 16%) sonic hedgehog (SHH; 21%) medulloblastomas virtually absent subgroups 3 4 tumors (P < .001). Patients...
Multiple independent genomic profiling efforts have recently identified clinically and molecularly distinct subgroups of ependymoma arising from all three anatomic compartments the central nervous system (supratentorial brain, posterior fossa, spinal cord). These advances motivated a consensus meeting to discuss: (1) utility current histologic grading criteria, (2) integration molecular-based stratification schemes in future clinical trials for patients with (3) therapy context molecular...
Purpose BRAF V600E is a potentially highly targetable mutation detected in subset of pediatric low-grade gliomas (PLGGs). Its biologic and clinical effect within this diverse group tumors remains unknown. Patients Methods A combined genetic institutional study patients with PLGGs long-term follow-up was performed (N = 510). Clinical treatment data mutated PLGG (n 99) were compared large international independent cohort mutated-PLGG 180). Results 69 405 (17%) across broad spectrum histologies...
Medulloblastoma comprises four distinct molecular subgroups: WNT, SHH, Group 3, and 4. Current medulloblastoma protocols stratify patients based on clinical features: patient age, metastatic stage, extent of resection, histologic variant. Stark prognostic genetic differences among the subgroups suggest that subgroup-specific biomarkers could improve prognostication.Molecular were identified from a discovery set 673 medulloblastomas 43 cities around world. Combined risk stratification models...
Optic pathway gliomas (OPGs) occur in 15%–20% of children with neurofibromatosis type 1 (NF1); up to half become symptomatic. There is little information regarding ophthalmologic outcomes after chemotherapy. A retrospective multicenter study was undertaken evaluate visual following chemotherapy for NF1-associated OPG, identify risks loss, and ascertain indications treatment. Subjects included undergoing initial treatment OPGs between January 1997 December 2007. Of 115 subjects, acuity (VA)...
Infant gliomas have paradoxical clinical behavior compared to those in children and adults: low-grade tumors a higher mortality rate, while high-grade better outcome. However, we little understanding of their biology therefore cannot explain this nor what constitutes optimal management. Here report comprehensive genetic analysis an international cohort clinically annotated infant gliomas, revealing 3 subgroups. Group 1 arise the cerebral hemispheres harbor alterations receptor tyrosine...
To uncover the genetic events leading to transformation of pediatric low-grade glioma (PLGG) secondary high-grade (sHGG).We retrospectively identified patients with sHGG from a population-based cohort 886 PLGG long clinical follow-up. Exome sequencing and array CGH were performed on available samples followed by detailed analysis entire cohort. Clinical outcome data genetically distinct subgroups obtained.sHGG was observed in 2.9% PLGGs (26 patients). Patients had high frequency nonsilent...